Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma

被引:3
|
作者
Molenaar-Kuijsten, Laura [1 ]
van Meekeren, Milan [2 ]
Verheijen, Remy B. [1 ]
Bovee, Judith V. M. G. [3 ]
Fiocco, Marta [4 ,5 ]
Thijssen, Bas [1 ]
Rosing, Hilde [1 ]
Huitema, Alwin D. R. [1 ,6 ,7 ]
Miah, Aisha B. [8 ,9 ]
Gelderblom, Hans [2 ]
Haas, Rick L. M. [10 ,11 ]
Steeghs, Neeltje [12 ]
机构
[1] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pharm & Pharmacol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[2] Leiden Univ, Med Ctr, Dept Med Oncol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Pathol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[4] Leiden Univ, Math Inst, Niels Bohrweg 1, NL-2333 CA Leiden, Netherlands
[5] Leiden Univ, Med Ctr, Sect Med Stat, Dept Biomed Data Sci, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[6] Univ Utrecht, Univ Med Ctr Utrecht, Dept Clin Pharm, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[7] Princess Maxima Ctr Pediat Oncol, Dept Pharmacol, Heidelberglaan 25, NL-3584 EA Utrecht, Netherlands
[8] Royal Marsden Hosp, Dept Clin Oncol, 15 Cotswold Rd, London SM2 5NG, England
[9] Inst Canc Res, 15 Cotswold Rd, London SM2 5NG, England
[10] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Radiotherapy, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[11] Leiden Univ, Med Ctr, Dept Radiotherapy, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[12] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Med Oncol & Clin Pharmacol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
关键词
intra-tumoral drug concentration; neoadjuvant treatment; pharmacokinetics; tyrosine kinase inhibitor; pazopanib; soft tissue sarcoma; GROWTH-FACTOR TREATMENT; VASCULAR NORMALIZATION; KINASE INHIBITORS; LUNG-CANCER; ANGIOGENESIS; OXYGENATION; RADIATION; EXPOSURE; SURVIVAL; PLASMA;
D O I
10.3390/cancers13225780
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary: Pazopanib plasma levels have been associated with treatment efficacy. Since pazopanib targets receptors present on cells in the vicinity of the tumor and on tumor cells themselves, measurement of pazopanib concentrations in tumor tissue might be an even better prognostic biomarker than plasma levels. The aim of our study was to quantify pazopanib concentrations in tumor tissue, correlate this with plasma concentrations, and assess whether this is a better biomarker for efficacy. A modest correlation was found between pazopanib tumor concentrations and plasma concentrations. Additionally, no correlation was found between pazopanib tumor concentrations and efficacy. We provide recommendations for future studies in which pazopanib concentrations are measured. There is a lack of understanding whether plasma levels of anticancer drugs (such as pazopanib) correlate with intra-tumoral levels and whether the plasma compartment is the best surrogate for pharmacokinetic and pharmacodynamic evaluation. Therefore, we aimed to quantify pazopanib concentrations in tumor tissue, to assess the correlation between tumor concentrations and plasma concentrations and between tumor concentrations and efficacy. In this clinical trial, non-metastatic STS patients were treated with neo-adjuvant concurrent radiotherapy and pazopanib. Plasma samples and tumor biopsies were collected, and pazopanib concentrations were measured using liquid chromatography-tandem mass spectrometry. Twenty-four evaluable patients were included. The median pazopanib tumor concentration was 19.2 mu g/g (range 0.149-200 mu g/g). A modest correlation was found between tumor concentrations and plasma levels of pazopanib (rho = 0.41, p = 0.049). No correlation was found between tumor concentrations and percentage of viable tumor cells (p > 0.05); however, a trend towards less viable tumor cells in patients with high pazopanib concentrations in tumor tissue was observed in a categorical analysis. Possible explanations for the lack of correlation might be heterogeneity of the tumors and timing of the biopsy procedure.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Pazopanib for metastatic soft-tissue sarcoma Reply
    van der Graaf, Winette
    Judson, Ian
    Dei Tos, Angelo Paolo
    Litiere, Saskia
    Blay, Jean-Yves
    LANCET, 2012, 380 (9844): : 801 - 801
  • [2] Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study
    Koca, Sinan
    Besiroglu, Mehmet
    Ozcelik, Melike
    Karaca, Mustafa
    Bilici, Mehmet
    Hacioglu, Bekir
    Dogu, Gamze G.
    Kaplan, Nihal B.
    Oruc, Zeynep
    Aydin, Dincer
    Dane, Faysal
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (03) : 541 - 546
  • [3] Pazopanib for the treatment of metastatic nonadipocytic soft-tissue sarcoma.
    Aydin, Fazil
    Topcu, Turkan Ozturk
    Ozdemir, Feyyaz
    Sahin, Nazim Onur
    Kavgaci, Halil
    Kandaz, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients
    Eastley, Nicholas
    Sommer, Aurore
    Ottolini, Barbara
    Neumann, Rita
    Luo, Jin-Li
    Hastings, Robert K.
    McCulloch, Thomas
    Esler, Claire P.
    Shaw, Jacqueline A.
    Ashford, Robert U.
    Royle, Nicola J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 14
  • [5] Trends in Survival for Patients With Metastatic Soft-Tissue Sarcoma
    Italiano, Antoine
    Mathoulin-Pelissier, Simone
    Le Cesne, Axel
    Terrier, Philippe
    Bonvalot, Sylvie
    Collin, Francoise
    Michels, Jean-Jacques
    Blay, Jean-Yves
    Coindre, Jean-Michel
    Bui, Binh
    CANCER, 2011, 117 (05) : 1049 - 1054
  • [6] Hypofractionated radiotherapy for non-metastatic bone and soft tissue sarcomas
    Sari, S. Yuce
    Cengiz, M.
    Dauletkazin, A.
    Yazici, G.
    Gultekin, M.
    Hurmuz, P.
    Yildiz, F.
    Zorlu, F.
    Gurkaynak, M.
    Akyol, F.
    Ozyigit, G.
    CANCER RADIOTHERAPIE, 2019, 23 (08): : 853 - 859
  • [7] EFFICACY OF IFOSFAMIDE IN COMBINATION WITH DOXORUBICIN FOR THE TREATMENT OF METASTATIC SOFT-TISSUE SARCOMA
    BLUM, RH
    EDMONSON, J
    RYAN, L
    PELLETIER, L
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 31 : S238 - S240
  • [8] Non-metastatic cholestatic paraneoplastic syndrome associated with soft tissue sarcoma
    Bal, Amanjit
    Dutta, Usha
    Das, Ashim
    Kocchar, Rakesh
    Singh, Kartar
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (02) : 137 - 141
  • [9] Radiotherapy for spinal cord compression in patients with soft-tissue sarcoma
    Merimsky, O
    Kollender, Y
    Bokstein, F
    Issakov, J
    Flusser, G
    Inbar, MJ
    Meller, I
    Bickels, J
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (05): : 1468 - 1473
  • [10] REOPERATIVE PULMONARY RESECTION IN PATIENTS WITH METASTATIC SOFT-TISSUE SARCOMA
    POGREBNIAK, HW
    ROTH, JA
    STEINBERG, SM
    ROSENBERG, SA
    PASS, HI
    ANNALS OF THORACIC SURGERY, 1991, 52 (02): : 197 - 203